TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8923017

Group type: EXPERIMENTAL
Intervention: High consumption of vegetables and fruit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Micronutrients (vitamin C, vitamin E, beta-carotene, selenium, magnesium, zinc)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary fibre
Number of subjects: 0

Group type: COMPARATOR
Intervention: Various combinations of vitamins and minerals at supranutritional doses
Number of subjects: 0
Study: 1739545

Group type: EXPERIMENTAL
Intervention: Early tracheal intubation with thiopentone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control method (3 min of manual ventilation)
Number of subjects: 24
Study: 6391784

Group type: EXPERIMENTAL
Intervention: Droperidol 2.5 mg (for cisplatin >= 100 mg/sq m) or 1.25 mg (for subsequent doses < 100 mg/sq m)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Metoclopramide 2 mg/kg (for cisplatin >= 100 mg/sq m) or 1 mg/kg (for subsequent doses < 100 mg/sq m)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Prochlorperazine 5 mg (for both dosages of cisplatin)
Number of subjects: 25
Study: 31259802

Group type: EXPERIMENTAL
Intervention: Tightrope fixation (one knotless Tightrope)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Screw fixation (two 3.5 mm cortical positional screws)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Tightrope fixation
Number of subjects: 103

Group type: COMPARATOR
Intervention: Screw fixation
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Functional outcomes (FADI scores)
Number of subjects: 103
Study: 28754540

Group type: EXPERIMENTAL
Intervention: P3P (Personal Patient Profile‐Prostate) decision aid
Number of subjects: 392

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 392
Study: 27008285

Group type: EXPERIMENTAL
Intervention: Progressive relaxation therapy
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Cognitive stress
Number of subjects: 59

Group type: COMPARATOR
Intervention: Relaxation
Number of subjects: 59
Study: 24170102

Group type: EXPERIMENTAL
Intervention: Tetracosactide (ACTH1‐24) therapy
Number of subjects: 13
Study: 22186968

Group type: EXPERIMENTAL
Intervention: Prehospital loading dose of 600 mg clopidogrel
Number of subjects: 337

Group type: COMPARATOR
Intervention: Standard therapy (clopidogrel administered after diagnostic angiogram)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Prehospital loading dose of 600 mg clopidogrel (treated patients)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Standard therapy (treated patients)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 337
Study: 20107434

Group type: EXPERIMENTAL
Intervention: Varenicline 0.5 mg b.i.d.
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg b.i.d.
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg b.i.d. (Male)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg b.i.d. (Female)
Number of subjects: 2000
Study: 17327628

Group type: EXPERIMENTAL
Intervention: Graves' Disease group
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study: 14551147

Group type: EXPERIMENTAL
Intervention: Second-generation oral contraceptive (30 microg ethinylestradiol/150 microg levonorgestrel)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Third-generation oral contraceptive (30 microg ethinylestradiol/150 microg desogestrel)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Progestagen-only preparations
Number of subjects: 86
Study: 11216928

Group type: EXPERIMENTAL
Intervention: Second-line protease inhibitor regimen (specific PIs include indinavir and nelfinavir)
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: Second-line protease inhibitor regimen with added nucleosides
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: Higher viral load at starting second PI
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: Lower CD4 cell count at starting second PI
Number of subjects: 984
Study: 9522133

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.3 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous femoral 3-in-1 block with 0.5% bupivacaine 2 mg kg-1
Number of subjects: 40
Study: 8026196

Group type: EXPERIMENTAL
Intervention: D‐beta‐hydroxybutyrate infusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control solution
Number of subjects: 12
Study: 2644580

Group type: EXPERIMENTAL
Intervention: RS-86 (cholinergic agonist)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 193743

Group type: EXPERIMENTAL
Intervention: Otoseptil Ear Drops
Number of subjects: 58

Group type: COMPARATOR
Intervention: Otosporin Ear Drops
Number of subjects: 58
Study: 31521496

Group type: EXPERIMENTAL
Intervention: Lavage Treatment (LT) group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dependent Drainage (DD) group
Number of subjects: 60
Study: 28235691

Group type: EXPERIMENTAL
Intervention: Sleep deprivation condition (29 consecutive hours awake)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control condition (normal sleep)
Number of subjects: 40
Study: 25548861

Group type: EXPERIMENTAL
Intervention: 3-week sensory cueing treatment
Number of subjects: 12

Group type: COMPARATOR
Intervention: 3-week sham treatment
Number of subjects: 12
Study: 24703167

Group type: EXPERIMENTAL
Intervention: 12-week Iyengar yoga intervention
Number of subjects: 31

Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 31
Study: 22824168

Group type: EXPERIMENTAL
Intervention: L-Carnitine (4 g) for 12 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 19670114

Group type: EXPERIMENTAL
Intervention: Harmonic Ultrasonic scalpel
Number of subjects: 51

Group type: COMPARATOR
Intervention: Scissors and hemostatic clips
Number of subjects: 51
Study: 18154124

Group type: EXPERIMENTAL
Intervention: Cisplatin 6 mg/m2 intravenously, daily; Radiation therapy: 2 Gy per fraction, 5 times a week, up to 68-70 Gy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin 40 mg/m2, weekly; Radiation therapy: 2 Gy per fraction, 5 times a week, up to 68-70 Gy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2, once in 3 weeks; Radiation therapy: 2 Gy per fraction, 5 times a week, up to 68-70 Gy
Number of subjects: 0
Study: 15131005

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitor (ramipril)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: AT1 antagonist (valsartan)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (valve replacement for mitral stenosis)
Number of subjects: 64
Study: 11588449

Group type: EXPERIMENTAL
Intervention: Normothermic bypass (36 degrees C, n = 8)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Hypothermic CPB (32 degrees C, n = 13)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study: 9442789

Group type: EXPERIMENTAL
Intervention: Deliberate overcorrection (50%) in patients with minimal haze after first PRK
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Exact retreatment in patients with minimal haze after first PRK
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Exact retreatment in patients with significant haze (> or = 2+ haze)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Deliberate overcorrection (50%) in patients with significant haze (> or = 2+ haze)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 106
Study: 8801333

Group type: EXPERIMENTAL
Intervention: TD-A (microporous membrane/acrylic adhesive)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: TD-B (microporous membrane/silicone adhesive)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: TD-C (microporous membrane)
Number of subjects: 10
Study: 2083043

Group type: EXPERIMENTAL
Intervention: Dentifrice containing 0.3% triclosan and 2.0% copolymer in a 0.243% sodium fluoride silica base
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Dentifrice containing 0.3% triclosan and 2.0% copolymer in a 0.76% sodium monofluorophosphate alumina base
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 147
Study: 464673

Group type: EXPERIMENTAL
Intervention: 5% dextrose with an amino acid solution containing 22% BCAAs
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 5% dextrose with an amino acid solution containing 35% BCAAs
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 5% dextrose with an amino acid solution containing 100% BCAAs
Number of subjects: 35

Group type: COMPARATOR
Intervention: 5% dextrose only
Number of subjects: 35
Study: 31075393

Group type: EXPERIMENTAL
Intervention: THC (dronabinol; 5-50 mg, dose individually tailored)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (identical to THC)
Number of subjects: 54
Study: 27402452

Group type: EXPERIMENTAL
Intervention: Automated low glucose insulin suspension system (intervention nights)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control nights (system not activated)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Duration of pump suspension
Number of subjects: 82
Study: 25541530

Group type: EXPERIMENTAL
Intervention: Induction of labor
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion
Number of subjects: 1391

Group type: COMPARATOR
Intervention: Expectant management (in WOMB trial)
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: Elective and emergency cesarean section
Number of subjects: 1391

Group type: COMPARATOR
Intervention: Vaginal delivery
Number of subjects: 1391
Study: 25301831

Group type: EXPERIMENTAL
Intervention: LVEF >50%
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: LVEF 36%-50%
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Patients with all 6 factors associated with LVEF normalization
Number of subjects: 752
Study: 22559906

Group type: EXPERIMENTAL
Intervention: ARNP-directed intervention including discussions of hospice benefits and advanced directives (Five Wishes document)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 26
Study: 19770386

Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m(2) twice weekly plus rituximab 375 mg/m(2) weekly for 4 weeks (arm A)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Bortezomib 1.6 mg/m(2) weekly plus rituximab 375 mg/m(2) weekly for 4 weeks (arm B)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (not specified, but implied as single-agent rituximab in ongoing phase III study)
Number of subjects: 81
Study: 17803818

Group type: EXPERIMENTAL
Intervention: ProAlgaZyme (4 fl oz daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Water placebo
Number of subjects: 60
Study: 15249319

Group type: EXPERIMENTAL
Intervention: Paracetamol 4 g/day (n = 405)
Number of subjects: 779

Group type: COMPARATOR
Intervention: Placebo (n = 374)
Number of subjects: 779

Group type: EXPERIMENTAL
Intervention: Paracetamol (n = 63) in chronic mechanical knee pain subgroup
Number of subjects: 779

Group type: COMPARATOR
Intervention: Placebo (n = 60) in chronic mechanical knee pain subgroup
Number of subjects: 779
Study: 12212663

Group type: EXPERIMENTAL
Intervention: 0.2 mg clonidine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 30 mg yohimbine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10325993

Group type: EXPERIMENTAL
Intervention: Hs + Ad group (Hartmann's solution containing 0.5 ml of 1:1000 adrenaline per 500 ml)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hs group (Hartmann's solution alone)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hs + Ad group
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 10
Study: 7704169

Group type: EXPERIMENTAL
Intervention: Tetravalent vaccine
Number of subjects: 1278

Group type: EXPERIMENTAL
Intervention: Serotype 1 vaccine
Number of subjects: 1278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1278
Study: 2497131

Group type: EXPERIMENTAL
Intervention: Pulsatile s.c. FSH
Number of subjects: 31

Group type: COMPARATOR
Intervention: i.m. FSH
Number of subjects: 31
Study: 504973

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin (s.c.) injected twice a day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intravenous heparin (i.v.) given by continuous perfusion
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 48
Study: 30734016

Group type: EXPERIMENTAL
Intervention: Chemotherapy administration
Number of subjects: 15057

Group type: EXPERIMENTAL
Intervention: Gastric resections
Number of subjects: 15057

Group type: EXPERIMENTAL
Intervention: Relative survival rate
Number of subjects: 15057
Study: 28460479

Group type: EXPERIMENTAL
Intervention: Ramucirumab
Number of subjects: 8405

Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 8405

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 8405
Study: 26062880

Group type: COMPARATOR
Intervention: Triple treatment (lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Dual treatment (lopinavir-ritonavir plus lamivudine)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Triple treatment
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Dual treatment
Number of subjects: 250
Study: 23385647

Group type: EXPERIMENTAL
Intervention: Fenofibrate 160 mg/day
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 21248328

Group type: COMPARATOR
Intervention: C:SH diet fed ad libitum for 28 d
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: C:WM:20DDGS diet
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: C:SH:10DDGS diet
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: Limit feeding diets containing DDGS at levels of 65 or 55 g/hen per day during the molt period
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 672
Study: 19837435

Group type: EXPERIMENTAL
Intervention: Solifenacin plus tamsulosin
Number of subjects: 398

Group type: COMPARATOR
Intervention: Placebo plus tamsulosin
Number of subjects: 398
Study: 17085151

Group type: EXPERIMENTAL
Intervention: Aprepitant 160 mg once daily for 8 weeks
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 17125603

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV, DAIDING)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Lamivudine (LAM)
Number of subjects: 209
Study: 14512778

Group type: EXPERIMENTAL
Intervention: Special Intervention (SI) - Internet-based program for 6 months
Number of subjects: 104

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 104
Study: 11776118

Group type: EXPERIMENTAL
Intervention: Etimicin
Number of subjects: 65

Group type: COMPARATOR
Intervention: Netilmicin
Number of subjects: 65
Study: 8653330

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 108

Group type: COMPARATOR
Intervention: Cervical lymphadenectomy
Number of subjects: 108

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 108
Study: 2004322

Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy (external irradiation to a dose of 5000 cGy in 5 weeks)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group (no adjuvant therapy)
Number of subjects: 172
Study: 6674819

Group type: EXPERIMENTAL
Intervention: Chlormethiazole (Heminevrin)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chlordiazepoxide (Librium)
Number of subjects: 40
Study: 29739753

Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 342

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 342
Study: 27916699

Group type: EXPERIMENTAL
Intervention: Home-based exercise training program (4 months), including pedometer, elastic resistance bands, DVD, training manual, calendars, log-book, video coaching calls, newsletters
Number of subjects: 57

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 57
Study: 26077795

Group type: EXPERIMENTAL
Intervention: Physician-pharmacist collaborative management (PPCM) model
Number of subjects: 539

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 539
Study: 23104435

Group type: EXPERIMENTAL
Intervention: Generalized linear model framework for data synthesis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian approach to estimation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of deviance information criterion
Number of subjects: 0
Study: 20969601

Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU) 200 mg twice daily for 7 days
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU) 200 mg twice daily for 7 days with finasteride 0.5 mg twice daily
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU) 200 mg twice daily for 7 days with finasteride 1.0 mg twice daily
Number of subjects: 11
Study: 19004202

Group type: EXPERIMENTAL
Intervention: Midnight-noon ebb-flow method of selecting acupoints (MNEFMSA)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Affected-channel group (acupuncture at points along the affected channel)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Drug group (routine medication)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: MNEFMSA group
Number of subjects: 90

Group type: COMPARATOR
Intervention: All groups (including MNEFMSA, affected-channel, and drug)
Number of subjects: 90
Study: 16915024

Group type: EXPERIMENTAL
Intervention: Moderate-intensity resistance training (MODE)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Combined resistance training and endurance training (COMBO)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sedentary control (CONTROL)
Number of subjects: 39
Study: 15129702

Group type: EXPERIMENTAL
Intervention: Maximal standardized uptake values (SUV) in the mediastinal metastasis group (4.9 +/- 1.8)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Maximal SUV cut-off value of 3.4
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Maximal SUV
Number of subjects: 70

Group type: COMPARATOR
Intervention: Maximal SUV in normal subjects
Number of subjects: 70
Study: 11763952

Group type: EXPERIMENTAL
Intervention: Essential oil‐containing (EOC) dentifrice
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vehicle control (VC)
Number of subjects: 12
Study: 9314461

Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate alone
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate
Number of subjects: 81

Group type: COMPARATOR
Intervention: Sodium stibogluconate plus allopurinol
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate alone and sodium stibogluconate plus allopurinol
Number of subjects: 81
Study: 8269208

Group type: EXPERIMENTAL
Intervention: m7E3 Fab (0.15 to 0.35 mg/kg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Aspirin (325 mg orally per day)
Number of subjects: 23
Study: 3518384

Group type: EXPERIMENTAL
Intervention: Hydralazine (mean titrated dose 96 +/- 9 mg, mean treatment dose 63 +/- 21 mg administered 3 times daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 30200078

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly (ETN50)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 64
Study: 27441577

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotic (cefazolin 2 g 30 min before surgery with repetition at 1 g every 3 h during surgery)
Number of subjects: 150

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis (Control)
Number of subjects: 150
Study: 21799164

Group type: EXPERIMENTAL
Intervention: Progression of carotid luminal narrowing over 1 year
Number of subjects: 1469

Group type: EXPERIMENTAL
Intervention: Ipsilateral neurological events
Number of subjects: 1469

Group type: EXPERIMENTAL
Intervention: Diabetes and previous contralateral symptoms
Number of subjects: 1469

Group type: EXPERIMENTAL
Intervention: High rates of progression
Number of subjects: 1469

Group type: EXPERIMENTAL
Intervention: Low progression rates or regression
Number of subjects: 1469
Study: 23087488

Group type: EXPERIMENTAL
Intervention: Perphenazine (typical antipsychotic medication)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Newer atypical antipsychotics
Number of subjects: 0
Study: 20729148

Group type: EXPERIMENTAL
Intervention: Memantine (20 mg per day)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study: 18728923

Group type: EXPERIMENTAL
Intervention: MAS063DP (Atopiclair), applied three times per day for up to 50 days
Number of subjects: 218
Study: 15930018

Group type: EXPERIMENTAL
Intervention: Calcium Carbonate (CC)
Number of subjects: 72
Study: 12697116

Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng injection
Number of subjects: 123

Group type: COMPARATOR
Intervention: Cisplatin-based chemotherapy without Shenqi Fuzheng injection
Number of subjects: 123
Study: 10965085

Group type: EXPERIMENTAL
Intervention: Clinical BP control (BP <140/90 mm Hg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ABPM control (BP during daytime <132/85 mm Hg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both clinical and ABPM control
Number of subjects: 100

Group type: COMPARATOR
Intervention: Uncontrolled patients
Number of subjects: 100
Study: 9162613

Group type: EXPERIMENTAL
Intervention: Troglitazone (400 mg day(‐1))
Number of subjects: 291

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study: 1996588

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 79

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 79
Study: 6504620

Group type: EXPERIMENTAL
Intervention: Pacifiers (non-nutritive sucking)
Number of subjects: 144

Group type: COMPARATOR
Intervention: No pacifiers (control)
Number of subjects: 144